Investors are closely watching the beverage giant's Q3 results on Monday for insights into the health of the alcoholic beverage market.
First patients implanted with the novel neurostimulator marks a key step in challenging market leader Inspire Medical after recent FDA approval.
The designation for ALTO-101 targets cognitive impairment, a debilitating condition with no currently approved treatments, signaling a major regulatory milestone.
Predictive Discovery and Robex Resources merge, creating a mid-tier producer targeting over 400,000 ounces of gold annually.
Conditional approval for Dectomax-CA1 addresses a significant threat to the U.S. livestock industry, boosting company shares.
Applied Materials forecasts a $600 million revenue hit, signaling broader disruption for the global chip industry amid escalating US-China tech tensions.
Strategic acquisition aims to bolster Firefly's national security and defense capabilities, expanding its space and defense mission services.
Early results for ARV-102, a novel PROTAC LRRK2 degrader, show the experimental therapy is well-tolerated and demonstrates key biomarker engagement.